GaDia SA is part of the TOP100 Swiss Startup Award!
To support GaDia and our work, please vote for us:
GaDia and click on VOTE NOW
Augurix SA, with their partner in Asia and support of GaDia SA, is launching on Swiss Market the first rapid serological test for COVID-19.
If you are admitted into a hospital you have 10% risk of contracting a Healthcare-acquired infection (nosocomial disease) according to WHO report 2011. These infections kill more than car crashes or breast cancer.
GaDia is Swiss startup developing an innovative, patented rapid in vitro diagnostic (IVD) test to detect nosocomial diseases. More specifically the aim is to develop a new rapid Point-Of-Care (POC) predictive diagnostic test to discriminate healthcare-acquired fungal infections from other causes of infections.
Bring Complex Diagnostics to Patient’s Bed
When time matters! GaDia reinvents the diagnostic of life-threatening diseases to quickly provide the right information to healthcare professionals.
The challenge of nosocomial
According to the World Health Organization (WHO), Healthcare-Acquired Infections (HCAI) or nosocomial diseases are the leading cause of preventable deaths and their prevalence are 7-15% of the hospitalized population.
The risk of being infected by HCA infections is significantly higher in intensive care units (ICUs), with approximately 30% of patients affected by at least one episode of HCA Infection. The mortality attribuable to nosocomial disease is estimated between 20-50%.
Annual financial expenses due to HCA Infections are estimated at approximately EUR 7 billion in Europe, direct costs only and reflecting 16 million extra days of hospital stay.
Fungi are major pathogens in critically ill patients and invasive fungal infection are often rapidly life-threatening and require prompt diagnosis and treatment. Colonization by fungal pathogens, more specifically Candida sp., is very common by hospitalized patients. The evolution of Candida spp. colonization to bloodstream infections (candidemia) is associated to an overall mortality ranged up to 70% .
The efficacy of anti-fungal treatments is lowered by a long and complicated diagnostic process. The challenge of GaDia is to reduce the overall mortality by decreasing the time-decision making process to start the adequate targeted therapy.
According to GaDia’s goal of reducing mortality of Healthcare-Acquired Infections, the tool that GaDia is developing is a predictive rapid test for early identification of fungal infections. This rapid and predictive in vitro diagnostic (IVD) test discriminates fungal infections (especially Candida sp.) from others life-threatening Healthcare-Acquired Infections.
GaDia innovation is the combination of newly targeted and patented biomarkers specific to fungal infections. The test is performed at patient bed (Point of care), is easy-to-use and rapid (15 minutes), reducing the risk of wrong interpretation. Moreover, the science used allows GaDia to predictively detect the fungal infections 2-4 days before it reaches the systemic stage (Bloodstream Infection or sepsis), therefore reducing mortality.
About GaDia SA
GaDia was founded in 2019 and is located in the BioArk in Monthey (Switzerland).
The project was initiated by Percevent J Ducrest (MSc), graduated from University of Applied Sciences Western Switzerland (HES-SO) and Bern University of Applied Sciences (BFH). Percevent received a grant from The Ark Foundation in 2018 to continue the assay development. He has conducted several R&D projects for external companies in the field of in vitro diagnostic tests and microbiology. In 2019, 2 C-level partners holding Bachelor and Master degrees in Finance and Management joined GaDia, bringing a wide expertise in corporate management positions in pharmaceutical and medical device businesses in Switzerland and abroad.
GaDia was finalist of the Prix Créateurs BCVs 2019.
Percevent J Ducrest – CEO & CSO
Frank D Harnischberg – COO
Marlène Iemolini – Sales & Marketing Manager
Julien Mottiez – CFO
Support and Partners